Abstract: This chapter examines the challenges involved in disseminating, integrating and analyzing large datasets collected on both human subjects and non-human experimental organisms, and within both clinical and research settings. I highlight some of the technical, ethical and epistemic concerns underlying current attempts to portray and use Big Data as revolutionary tools for producing biomedical knowledge and related interventions. When bringing together data collected on human subjects with data collected from other organisms, significant differences in the experimental cultures of biologists and clinicians emerge, which if left unchallenged risk to compromise the quality and validity of large scale, cross-species data integration. My study emphasises the complex conjunctions of biological and clinical practice, model organisms and human subjects, and material and virtual sources of evidence -thus emphasising the fragmented, localized and inherently translational nature of biomedical research, and the challenges underlying the assemblage and interpretation of big data in this domain.
Introduction
Big Data -the opportunity to assemble and analyze vast datasets produced at high speed and volume from several sources at once, thus promising to document in detail all aspects of phenomena under investigation -is hailed by many governments and funding agencies as a revolutionary tool for biomedicine (e.g. Hey et al. 2009; Kitching 2013; Cambrosio et al 2014; Tailor 2016 ). Its potential is thought to encompass a new relationship between patients and healthcare providers, and faster, more reliable and earlier diagnosis of disease. It is believed that it will offer a better understanding of the treatments likely to have a therapeutic effect based on the availability of larger bodies of evidence that can be statistically analyzed (e.g. Solomon 2015) , and more precise understandings of the underlying causes of disease based on the integration of data from human subjects and non-human models (e.g. Clarke et al 2014) . In this chapter, I focus on the promise of big biomedical data to improve current understandings of disease. I examine the infrastructure needed to assemble, integrate and analyse the relevant big data and focus particularly on the ways in which online databases collecting human and nonhuman data are developed and maintained, with the aim of illustrating the opportunities and the challenges involved in such an exercise of data stewardship.
This work builds on long-standing efforts within STS scholarship to note and investigate the role played by online databases within science, including its impact on the organization, order and communication of research outputs (e.g. Hilgartner 1995 , Leigh Star and Rhleder 1996 , Bowker 2001 , Wouters and Schroeder 2003 , Hine 2006 and more recently Edwards et al 2011 , Stevens 2013 , Borgman 2015 . The dissemination of data through electronic means is now an essential complement to the publication of research papers and the consultation of online, widely accessible databases has become part and parcel of everyday routines within experimental research (Lenoir 1999) . The heightened need for specialist skills in computer programming has also affected the division of research labor and the ways in which scientists are trained. While university curricula in natural science are giving new prominence to information technologies and data science, database "curators" have emerged as a professional figure whose responsibilities lie in developing databases that satisfy the needs of prospective user communities (Baker and Millerand 2010; Chow-White and Garcia-Sanchos, 2011; Leonelli 2016) . The impact of online resources is particularly evident within the biological and biomedical sciences, where research communities dedicated to the study of popular model organisms have developed sophisticated databases for the organization, dissemination and comparative analysis of genomic data coming from different species (Leonelli and Ankeny 2012) . These tools are often treated as a model for how cross-species data mining should be organized. This has special relevance for the development of information infrastructures for post-genomic, molecular-based medicine, which requires digital platforms through which data on human and non-human organisms can be integrated and compared. Indeed, the databases developed within model organism biology have been hailed as critical to "unlocking the very essence of biologic life and enabling a new generation of medicine" (Buetow 2005) . Databases are expected to facilitate the achievement of these ambitious goals by fostering the integration of biological and biomedical knowledge, thus supporting translational research towards new forms of diagnosis and treatment.
This chapter investigates the role played by databases in facilitating the collection and use of big data in biomedicine through an examination of the practical difficulties encountered by database curators in fulfilling this task. The hype attached to database development as an easy solution to the deluge of data of biomedical relevance, coming from clinical trials and laboratory experimentations, as well as patient records, observational studies and health apps, has taken attention away from the problems involved in actually using data found online towards further research. In particular, matching in silico representations of the world with experimentation in vivo and in clinical intervention, and aligning the experimental practices characterizing research on humans with the ones used to research non-human organisms present significant challenges. I view database development not primarily as a means towards the solution of those problems, but rather as a site where diverging stakes, values and epistemologies characterizing experimental cultures in biomedicine can be identified and discussed, thus highlighting the opportunities and challenges associated with the assemblage and integration of vast datasets derived from very different sources and methods.
The use of cross-species databases is an excellent instance of 'biomedicine', defined as the set of practices which brings biological and clinical knowledge and techniques to bear on each other (Keating and Cambrosio 2003) . Historians and sociologists of medicine have pointed to the extensive fragmentation characterizing the epistemic communities involved in biomedical research and have analyzed the complex relations and intersections between them (e.g. Loewy 1986, Quirke and Gaudillière 2008) . Science and technology studies scholarship has documented how scientists attempt to overcome this pluralism in order to achieve common standards and procedures, for instance in the case of clinical trials (Kohli-Laven et al 2011) , the trading of biological data and materials (Parry 2004) , and the standardization of microarray experiments (Rogers and Cambrosio 2007) . Database curation is another area where the introduction of standards, norms and specific technologies clashes with a highly fragmented and localized landscape of research habits and practices. This holds especially when considering the materials -the organisms -on which data are produced and disseminated. While some clinical research is conducted on humans, much clinical work involves the collection and use of data acquired on rats, mice and other, more distant relatives of Homo sapiens (Spradling et al 2006) . Similarly, biological research largely revolves around few key model organisms, such as the nematode Caernorhabditis elegans, the fruit-fly Drosophila melanogaster, the thale-cress Arabidopsis thaliana and the zebrafish Danio rerio (Davies 2004 ). Database curators can contribute different skillsets depending on the history and aims of the specific database at hand, and indeed their backgrounds can range from information engineering to bioinformatics, experimental biology or medical training. Their familiarity with the organisms whose data they are stewarding can thus vary substantially. Curators are typically aware of their important role in facilitating the comparison and integration of data on humans with data on model organisms. They are also aware that the success of their products depends on how useful they prove to be to experimenters, as this determines the levels of funding and community support that they will receive. Thus, the career of curators depends at least in part on their ability to identify, embrace and constructively engage as many epistemic cultures in biomedicine as possible, which, in practice, means making their digital representation of data at least compatible with, and at best conducive to, widely diverse forms of intervention on actual organisms (Leonelli 2016) . This inescapable commitment makes curators' insights into the interface between biology and medicine and the experimental cultures that characterize these two realms uniquely informative and valuable.
Model Organism Databases and the Incorporation of Human Data
Within model organism biology, huge efforts have been invested in database development over the last two decades (Bult 2006) . These investments were fueled by the growing recognition, across biomedicine as a whole, that collection and dissemination practices affect whether and how data are re-used towards new discoveries (Buetow 2005) . Moreover, the extent to which model organism communities have engaged in database development is linked to their unique historical role in fostering a collaborative ethos within the notoriously competitive culture of biomedical research. Many of the most popular models, including the fruit-fly, the thale-cress, the nematode and both baker and fission yeast, owe some of their success as laboratory organisms to the collaborative ethos and interdisciplinary ambitions fostered by the scientists who pioneered their use in biology (e.g. Kohler 1994 , Rader 2004 .
i Their explicit long-term goal was understanding organisms in all of their complexity through an interdisciplinary approach that would include genetics as well as cell biology, physiology, immunology, morphology and ecology. Their strategy to achieve this was to accumulate and integrate knowledge on the biology of individual species, which would then provide a blueprint and reference point for comparative, cross-species research. Over the last three decades, this attitude has been incorporated into the building of model organism databases, which are often referred to as 'community databases' to stress their role in serving researchers by gathering and integrating all the information available on a specific organism of interest to them (Vize and Westerfield 2015) .
These databases are freely accessible online thanks to public funding from national and international agencies, and have become an important component of the very identity and status of model organisms in research, on par with other characteristic features such as their capacity to represent other species, their tractability in the lab and the extent to which they embody biological processes of interest (Ankeny and Leonelli 2011 ii These databases were initially funded by public agencies to disseminate data coming out of sequencing projects. The curators of these databases took advantage of the funding to build tools to potentially incorporate other types of data on the same organism, and they have aimed to increase the diversity of the data that they host ever since. As a result of these efforts, the curators of these databases acquired a sophisticated understanding of the factors that influence the future adoption and use of data collected on model organisms across research contexts. These factors include the need to integrate different data types produced through various kinds of instruments and techniques, ranging from sequence data to photographs or tissue samples as well as the need to collect meta-data documenting the provenance of data. Further, database users want to be able to retrieve data through familiar keywords that they employ in their own research, and to be able to visualize data in a variety of ways, which helps with spotting significant patterns and correlations. Finally, users are typically interested in being able to access the organic materials on which data were originally acquired, such as specimens of a given mutant or a particular kind of tissue. Curators have proposed themselves as possessing the right skills to fulfil these complex requirements, and regular
Biocurator meetings are now held across the globe to facilitate cooperation and interoperability across different databases (Howe et al 2008) . On the basis of their growing expertise and increasing need for comparative analyses, the curators of community databases have also engaged in the development of cross-species databases, where existing data on different organisms can be searched, viewed and compared. A well-known initiative of this kind is the Gene Ontology (GO), a bio-ontology developed jointly by the curators of several community databases for the cross-species annotation of gene products (Gene Ontology Consortium 2000).
All the curators involved in GO hold a PhD in a branch of experimental biology and use that expertise to inform their curatorial activities. The GO currently includes data from dozens of species, including several grains, yeast, slime mold, rat, several microbes and Homo sapiens, and is coordinated by a central office at the European Bioinformatics Institute near Cambridge, UK.
iii Another important initiative is the Generic Model Organism Database project (GMOD), also referred to as the 'myriads' database because of the sheer number of species that it incorporates.
The GMOD project is the result of an extensive cooperation involving over 100 participating databases, including repositories of human data such as Human 2q33, Chromosome 7 Annotation project, Xmap, Ymap and HapMap. Its main goal is to help species-specific databases to coordinate their efforts, so as to guarantee interoperability across databases and thus facilitate cross-species analyses. To this aim, the GMOD encourages database curators to use a common set of software packages, such as tools for browsing and annotating genomes, and to take account of the standards already employed by the main model organism databases when setting up new tools and resources (GMOD 2016).
Thanks to initiatives such as GO and GMOD, several features of the community databases "A critical need is better cross-organism databases that enable one to compare the genes, expression patterns, gene functions, cell types, tissue organization, and biological subprocesses across organisms, including humans. Maintaining and expanding our community resources, such as mutant collection and siRNA libraries for many organisms, including those not amenable to standard genetic techniques, is crucial. They provide access to the genetic power of the different model organisms and enable investigators to take full advantage of whole-genome sequence information. Finally, we must look for ways to interact with clinician scientists and human geneticists and bring their knowledge and perspectives to the modeling efforts" (Spradling et al 2006) .
This quote indicates that clinicians have not been involved with developing cross-species databases, and that this lack of involvement needs to be remedied. This situation is puzzling especially since one of the key purposes of cross-species comparisons is to achieve a better understanding of humans, leading to improvements in medical knowledge, diagnosis and treatments. In the words of a curator interviewed in 2008, "model organism databases also included human because obviously people are interested in what goes on in human, so that gets included even though there isn't an organism database".
The curator is referring to the fact that, while there are hundreds of disease / system / organspecific human databases, there is no unique 'model organism database' for Homo sapiens.
There are practical reasons for this: the sheer diversity and scale of data collecting practices on human beings; the multiplicity of sites where such collections are taking place, and the impossibility of coordinating and standardizing the formats of collection; and the restriction to interoperability and access to human data, motivated by ethical concerns with privacy as well as by intellectual property, security and confidentiality issues in clinical research. If we stick to the above characterization of model organisms as ones on which all types of data can be collected and exchanged without restrictions, it is clear that Homo sapiens is not a model organism, nor could it become one in the future. Yet, in the context of cross-species databases, human data are often treated in the same way as data coming from model organisms.
This observation opens a host of ethical questions about privacy concerns and the status of individuals and populations in biomedical research, which are being examined by other chapters in this volume. In what follows, I wish to explore the differences in research practices that are brought to the fore by attempts to develop cross-species databases, and the resulting concerns for big biomedical data integration and analysis. I focus on four sets of issues that curators perceive to be emerging when human data are added to model organism databases. My analysis is based on a cross-examination of the content and guidelines of the GO and GMOD websites; and multisited ethnographic research on curation practices and database building carried out between 2004 and 2014, which included attendance at scientific meetings concerning biocuration in both model organism biology and medicine; visits to laboratories engaged in extensive bioinformatic work, including the development of cross-species databases; and extensive interviews with curators of cross-species databases based in the UK, Germany and the US.
Issue 1: Data
The first issue concerns a divergence in the criteria used to determine what counts as reliable evidence. The problem is exemplified by the unclear status of microarray data as a source of evidence about gene expression. A great deal of standardization of terminology, experimental protocols and instruments is required to describe a microarray experiment -and, at the same time, to make sure that the procedures and techniques used within such an experiment are intelligible and replicable across different laboratories. This is mainly because of the strong influence that even minute variations in a laboratory environment, such as a difference in temperature or lighting, can have on the results of a microarray experiment. However, it can also be due to the specific samples used, the ways in which instruments are calibrated, and the ways in which the original model organism was nurtured in the lab. The MIAME project, which stands for Minimal Information About a Microarray Experiment, has been set up precisely to address this need and streamline the process of agreeing upon, and implementing, such standards. Still, the development of standards such as MIAME has been fraught with difficulties and controversies (Roger and Cambrosio 2007) , and MIAME standards are still not universally The large amount of literature available on the human body makes it hard for curators to find references for their annotations and spot uncontroversial, consistent sources for their work.
Issue 2: Meta-Data
A second challenge for database curators is the lack of agreement on what information needs to be included about the experimental circumstances in which data are originally obtained -in other words, information about the provenance of data, the processes through which data was produced and formatted for dissemination (Bowker 2001, 664) . This information, technically referred to as meta-data, is crucial to assessing the evidential value and reliability of data found in a database. By accessing meta-data, users get to know who gathered the data of interest, the methods employed to do so and the research interests that motivated data production in the first place. These are all elements that help researchers to evaluate whether data are trustworthy, how they compare to other datasets available on the same phenomena and, as a result, what biological interpretation they could credibly support.
The gathering of meta-data is complicated by the fact that different labs disagree on what elements are crucial in describing the provenance of data (Edwards et al 2011) . Further, experimental protocols and procedures are constantly shifting, making it difficult to settle on fixed types of information as meta-data. Still, the curators of model organism databases argue for the importance of settling at least minimal standards for what counts as important information about an experiment (e.g. Taylor et al 2008) . The fundamental piece of information that needs to accompany each dataset is, unsurprisingly, the specific organism on which the data was obtained.
The very idea of comparing data obtained on different organism depends on clearly identifying the species, and sometimes even the individual specimen, on which the data were originally collected. And yet, precisely on this crucial point curators find that clinical and biological researchers differ in how they conduct and describe experiments. Clinical researchers are perceived as frequently mixing organic materials coming from different types of organisms.
According to the curators I interviewed, they often contaminate human samples with materials coming from other species -RNA probes coming from bacteria, for instance -and do not care to specify this when writing up their results. They sometimes even fail to specify whether they are working on human cells or mouse cells, on the grounds that they are convinced that this will not matter for their conclusions. This attitude clashes with the strict standards for annotating experimental materials and procedures adopted within model organism biology. This sometimes results in curators refusing to include data in a cross-species database, because they cannot classify them according to the organism on which they were originally acquired.
Further, curators are committed to distinguishing results acquired through experimental procedures (referred in the quote below as "primary annotations") from the interpretation of those results given by experimenters ("author statement", typically acquired by curators via direct queries to data producers). One of the worries underlying the contamination of samples is that experimenters tend to decide, on the basis of their own experience and of the specific circumstances in which data are produced, whether contamination is relevant or not to interpreting the results. iv The reasons for this important decision are thus kept tacit and inaccessible to the users of databases that report those data, who are left with the only option of trusting the scientific judgment (and thus the beliefs and expertise) of the original data producers.
This situation generates uneasiness among curators, since efficient data re-use is understood to involve the possibility to scrutinize (and if necessary, challenge) the beliefs and context in which data were originally produced. A consequence of such uneasiness is that human data on gene products are often annotated as author statements, because experiments are not carried out entirely on human tissue -which can be interpreted as indicating that these data are intrinsically less reliable and trustworthy.
One way to explain the perceived difference in the ways in which clinicians and biologists annotate their experimental results is to think of the different priorities and commitments involved in their daily activities. It is often said that while clinicians aim to cure, biologists aim to explain. This distinction cannot be applied too neatly to experimental cultures in the two realms, since they both attempt to understand biological processes (whether general processes like metabolism and development or specific syndromes such as breast cancer) and to successfully manipulate organisms. However, curators' perceptions of how experimenters annotate and assess their data point to some interesting differences in the ways in which biological and clinical experimental results are valued and used. These differences might be partly explained by the ways in which experimentation in the two realms is evaluated by funding bodies. While biologists are increasingly asked to produce results of social and economic relevance, the quality of biological research remains primarily assessed through peer review of papers resulting from research efforts. As a result, enhancing the quality and credibility of experimental research in biology involves documenting and validating the sources of the evidence used to back specific claims, so that peer reviewers reading the resulting documents are satisfied. By contrast, clinicians' experimental results are valued primarily for their fruitfulness in supporting effective treatment of patients, and thus there is less incentive to carefully document every step of their experimental procedures.
Issue 3: Materials
The third issue I wish to examine is the handling of materials relating to the data generated and disseminated in biological and clinical settings. In addition to the discussion above, another possible explanation for the difference in experimental annotations concerns the relationship built by researchers with the organisms that they study. This raises questions about the experimental procedures used to select, manipulate and standardize organisms, both individual specimens and parts such as tissues, cell cultures, blood, organs. Within model organism biology, the standardization of organisms is of paramount importance: being able to access specimens that are genetically and/or phenotypically identical to the ones on which experiments are carried out is seen as crucial to validating experimental results and pursuing research that builds on previous efforts (Rosenthal and Ashburner 2002) . Model organisms are standardized through two types of processes. The first consists of the processes of transformation from organisms found in the field to laboratory specimens that are easy to keep in a laboratory environment and use for experimental interventions (a set of features typically referred by researchers as the "tractability"
of an organism or species). The very act of transporting an organism into a laboratory environment occasions several changes to its biology (ranging from its physiology to its genome), due to the need to live in an environment where the basic rules of survival in the wild are subverted. Organisms are also often genetically modified to exhibit features suited to the research goals at hand (e.g. the oncomouse). The second type of standardization is the one involved in the dissemination of specimens and related findings across research communities.
For organisms to become favoured scientific materials, it is not sufficient that they are tractable in a laboratory environment and useful for the research that is carried out. The organisms themselves need to be able to travel across different labs, so that researchers can verify those results and/or further them through more experiments. This contributes to defining the characteristics of the organism selected for research: bigger organisms fare worse than smaller organisms and organisms that easily survive displacement are favoured.
v As illustrated by these procedures, the need to standardize guides and conditions all stages of researchers' interactions with model organisms. This situation is obviously different from the ways in which researchers interact with human subjects, and indeed neither of the two processes of standardization described above maps neatly onto the treatment of humans in clinical research.
Let us consider the process of transformation first. It is true that human subjects are selected as subjects for research according to their biological characteristics, including at times their genetic make-up or their ethnic background. vi Some clinical studies look for "adequate" populations across the globe -where adequate means representative of the traits that researchers wish to study, and/or amenable to the kind of treatment and sampling required for clinical research purposes. However, this latter interpretation of what constitutes adequate populations is under heavy ethical scrutiny. This is because the specific characteristics of the population being examined matter a great deal when attempting to establish the efficacy of a treatment, and yet many groups who may benefit from targeted medication have been historically excluded from acting as an adequate sample (e.g. children and pregnant women). Further, the notion that human beings might be used as instruments for research, to the point of infringing on their basic rights (among which the right to privacy), is extremely controversial (e.g. Waldby and Mitchell 2006, Sunder Rajan 2017) . Another possible parallel to the process of attempting to transform humans into a model organism is the way in which patients are "prepared" for participation in a clinical study, for instance through a specific diet and/or by imposing a set of appropriate behaviors and habits as a condition for participation (e.g. stopping to smoke or drink alcohol). Even when taking this into account, however, human subjects cannot be viewed as undergoing physical modifications comparable to the transformation of model organism specimens so as to fit research needs.
Turning now to the process of dissemination, the parallels with the treatment of model organisms This set of considerations adds another layer to curators' worries about extensive differences in how researchers treat organisms. Clinicians working on mice are much more likely to adhere to the practices recommended by database curators to describe their specimens, while researchers carrying out experiments on human subjects and their parts operate in quite a different experimental culture. It is then not surprising that, while clinicians working on humans were not involved in the initial effort to develop the GO, prominent representatives of the mouse community were among its founders.
Issue 4: Terminology
The last issue is the choice of terminology used to classify and retrieve data across organisms.
Already within model organism communities, the problem of choosing terms that different groups will recognize and understand is one of the most urgent issues confronted by curators.
Achieving terminological compatibility across the human/non-human boundary and across biological and clinical practice is even more daunting, especially given the efforts already invested by the medical community (e.g. the Medical Subject Heading created by the National Library of Medicine to index medical literature). Attempts to integrate the terminologies used in medicine with the ones used in biology have been under way for decades, and scientists are making headway especially when focusing on specific areas or diseases. To exemplify the issues that might emerge when merging vocabularies coming from model organism research and research on humans, I consider the recent merger of GO terms with the Unified Medical Language System (UMLS), a metathesaurus of 900,000 medical terms developed by the National Library of Medicine which is recognized as one of the most authoritative references for standard medical terminology (Nelson et al 2002; Bodenreider 2004) . Despite curators' published claims to the effect that the merger had been relatively smooth (Lomax and McCray 2004) , my interviews with the curators involved reveal that this attempt towards integration generated some interesting paradoxes and led to revisions of GO. For example, a key organizing principle within GO is to distinguish terms that describe a molecular function from terms that describe a biological process. Within medical discourse, such partition is hard to apply, since the molecular function of gene products is automatically equated with a characterization of the biological process in which that gene is involved; thus, the UMLS nomenclature does not classify its terms in this way. Even where terms overlap between the two nomenclatures, the meanings assigned to those terms might differ. Indeed, nomenclatures such as ULMS and GO are organized hierarchically through a series of relationships. Basic relationships in GO are mereological ('part_of') relationships and functional relationships such as "regulates". In contrast, ULMS uses a broader range of relationships including "physically related to," "spatially related to," "temporally related to," "functionally related to," and "conceptually related to". vii Given these differences in semantic structure, terms shift their meaning depending on where they are situated in the network -in much the same way as the interpretation of single words in everyday communication depends on the linguistic and social context in which they are used.
Another issue emerges in relation to the process through which curators select which terms should be used to classify given sets of data. In biology, annotations tend to be based on peerreviewed publications relating datasets to specific processes, functions or entities. In clinical research, it might be hard to find a direct, well-established link between a dataset and a term of interest -for instance, a disease. Still, there might be good reasons to suspect that such a link exists, and thus to annotate those data under the term referring to the disease in question. Trying to accommodate these different criteria is puzzling to curators trying to work on both realms.
This brings us back to the divergence in priorities discussed with reference to data assessment and meta-data annotation, and enables me to add a further layer to it. Clinical researchers can use incomplete information because, in their worldview, this is better than having no information at all. Biologists are typically more cautious in claiming causal links between biological processes, while clinicians are more used to take account of information deemed to be relevant to a given disease without fully understanding the mechanisms causing it. Thus, in biomedical research, any hint that points to the etiology or treatment of abnormal human phenotypes merits mention, whereas experimental research using similar data would be characterized as largely exploratory.
A more fundamental, conceptual problem with integrating nomenclatures across the human/nonhuman boundary concerns assumptions about the normal and the pathological. Databases such as GO have been built to focus on non-pathogenic entities and processes -which are referred to as "normal" (Gene Ontology Consortium 2000). The reason for this is that model organisms datasets are supposed to be representative for the biology of a wide set of organisms, and are thus conceptualized as documenting "typical" of "normal" gene functions found in a given species.
Clinical research on humans has almost the opposite connotation: because the main interest is in understanding and treating specific pathogenic conditions, cross-species research is centered on diseases and the vast majority of available human data document so-called "pathological states".
This situation causes problems when it comes to incorporate data on diseased organisms into GO, with the consequence of making cross-species databases potentially less interesting to clinical researchers. It also raises the philosophical question of what constitutes "pathogenesis"
and "normality" in the biological and clinical realms. This goes well beyond what I can tackle here, but it is important to mention since the way in which researchers answer this question deeply affects their conceptualization of how data should be collected, disseminated and interpreted.
Conclusion: Big Data Integration and Diverging Research Cultures in Biomedicine
I have singled out four challenges in the development of cross-species databases, which curators view as evidencing potential discrepancies between clinical and biological research practices: (1) the criteria for what counts as reliable evidence, (2) the selection of meta-data, (3) the standardization and description of research materials and (4) the choice of nomenclature used to classify data. The controversies surrounding these aspects of database development reveal their significance in demarcating, and possibly reinforcing, epistemic differences between the lab and the clinic and between human and non-human research. Both sides aim to understand and change the world. Yet, biologists use data collections as a way to extend and test their understanding of organisms, while clinicians view the accumulation of data as essentially aimed to treat patients.
This difference in emphasis is amplified by the evaluative cultures within these two realms.
Clinicians are working in an environment where research is evaluated both for its contributions to medical knowledge and for its impact on treating patients. Despite the increasing push towards applied research, this is not the same for biologists, whose outputs are evaluated mainly through their published outputs. This in turn reinforces differences in how biologists and clinicians generate, evaluate and disseminate data. Clinicians tend to use data that biologists consider to be potentially unreliable and to value causal information that biologists do not see as conclusive.
For them, inserting such information in databases means increasing the chance of gathering useful clues towards understanding phenomena of interest. By contrast, biologists fear that
lowering standards for what counts as evidence will weaken the overall reliability of data found in databases, which will in turn encourage misleading or even wrong interpretations. At the same time, many of the challenges listed above stem not from cultural divergences between clinicians and biologists, but rather from differences in the research practices of experimenters who work with non-human organisms and experimenters who work with humans. Clearly, experimenting on humans brings ethical, financial and material constraints that are not present in model organism research, which generate differences in the ways in which researchers communicate and process data.
Databases have become crucial sites for the encounter of those diverging cultures, the identification of differences and the expression of conflict (which may or may not pave the way to its resolution; Leonelli 2016) . The recent deluge of data is making it ever more difficult for biologists and clinicians to interpret the wealth of information found online in ways that help understanding the material bodies they work with -whether they are insects, plants, fungi, animals or humans. This process of aligning the informational with the material is specific to big data assemblages and analysis, and constitutes one of the foremost scientific challenges of the 21 st century. The divides between biologists and clinicians on the one hand, and human and nonhuman research on the other, make this alignment ever more complex to achieve; and the work done by database curators is key to confronting this challenge. How curators deal with pluralism in data production and interpretation is likely to have a huge effect on how different constituents of biomedical research relate to each other. The ways in which databases are structured, and the choice of which data gets included and how, can dilute or reinforce the differences in research cultures noted above, and provide a platform for critical and constructive discussion of how underlying disagreements and diversity in methods and materials can be handled when using big data assemblages as evidence for new medical claims and/or interventions.
